Advances in Targeting CD30 for Classic Hodgkin Lymphoma Therapy
CD30,a member of TNFR(tumor necrosis factor receptor)superfamily,is a type I trans-membrane protein that is localized to cell membrane.CD30 is only expressed in some activated B lymphocytes and T lymphocytes and involved in regulating the function of immune system.However,it is upregulated in a variety of lymphomas,especially in cHL(classical Hodgkin's lymphoma).Highly expressed CD30 promotes cHL progression through various mechanisms,such as activation of NF-κB,MAPK-ERK signaling pathway,and influence of tumor microenvironment to promote the proliferation and anti-apoptosis of cHL tumor cells.As it is highly overexpressed in cHL tumors and promotes disease progression,CD30 is a promising therapeutic target for cHL.BV(Brentuximab vedotin),a kind of CD30 related antibody-drug conjugate,has been approved for the clinical treatment of relapsed/refractory cHL.The clinical indications of BV have been rapidly expanded and significantly improved the prognosis of cHL patients.In addition to BV,several studies are working to develop other CD30-targeted therapies for cHL,such as CD30 monoclonal antibodies and CD30 CAR-T cells.The effec-tiveness of these treatments has confirmed by many preclinical studies and clinical trials.This review will sum-marize the expression and function of CD30 in cHL and cover the advances in targeting CD30 for cHL.
NETL
NSTL
万方数据
